Previous studies [4–7] have suggested that the involvement of TRPM7 in GBM is due to the channel's aberrant activity and up-regulation in the cancerous tissues by using techniques to reduce TRPM7 functions (i.e. knock down, or pharmacological inhibition). This evidence concerns the gene TRPM7 and glioblastoma.